Investigation of the susceptibilities of extended-spectrum beta-lactamase producing escherichia coli and klebsiella spp. strains to ertapenem and other carbapenems;Genişjemiş. Spektrumlu Beta-Laktamaz Üreten Escherichia coli ve Klebsiella spp. Suşlarinin Ertapenem ve Diǧer Karbapenemlere Karşi Duyarliliklarinin Araştirlmasi

Mikrobiyoloji Bulteni

Volumn 45, Issue 1, 2011, Pages 28-35

  Kuzucu, Çiǧdem ^a   Yetkin, Funda ^b   Görgeç, Sündüz ^a   Ersoy, Yasemin ^b  

^a INONU UNIVERSITY   (Turkey)

^b INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Carbapenemase; Ertapenem; ESBL; Modified hodge test

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; CARBAPENEM DERIVATIVE; ERTAPENEM; IMIPENEM; MEROPENEM; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HUMAN; KLEBSIELLA INFECTION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; IMIPENEM; KLEBSIELLA INFECTIONS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 79952166220     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18(4): 657-86.
2. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13(47): 1-11.
3. Canton R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008; 14(Suppl 1): 144-53. (Pubitemid 350269194)
4. Sorlózano A, Gutiérrez J, Romero JM, Luna JD, Damas M, Piédrola G. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli. J Basic Microbiol 2007; 47(5): 413-6. (Pubitemid 350003894)
5. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52(4): 538-42. (Pubitemid 37258409)
6. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16(2): 184-6.
7. Pillai DR, Melano R, Rawte P, et al. Klebsiella pneumoniae carbapenemase, Canada. Emerg Infect Dis 2009; 15(5): 827-9.
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth Informational Supplement. CLSI Document M100-S19, 2009. CLSI, Wayne, PA.
9. Kim JY, Sohn JW, Park DW, Yoon YK, Kim YM, Kim MJ. Control of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use. J Antimicrob Chemother 2008; 62(2): 416-21. (Pubitemid 351984791)
10. Poirel L, Villa L, Bertini A, Pitout JD, Nordmann P, Carattoli A. Expanded-spectrum beta-lactamase and plasmid-mediated quinolone resistance. Emerg Infect Dis 2007; 13(5): 803-5. (Pubitemid 46698763)
11. Mammeri H, Van De Loo M, Poirel L, Martinez-Martinez L, Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 2005; 49(1): 71-6. (Pubitemid 40065774)
12. Poirel L, Lartigue MF, Decousser JW, Nordmann P. ISEcp1 B-mediated transposition of blaCTX-M in Escherichia coli. Antimicrob Agents Chemother 2005; 49(1): 447-50. (Pubitemid 40065830)
13. Yetkin G, Kuzucu Ç, Çalişkan A, Ay S. Kan kültürlerinde üreyen Escherichia coli'lerin antibiyotik duyarlihklari, GSBL oranlan ve hastane birimlerine göre daǧilimi. Inönü Üniv Tip Fak Derg 2006; 13(3): 147-50.
14. Kizirgil A, Yakupoǧullan Y, Jenol FF, Toraman ZA. Kan kültürü örneklerinde genişlemiş spektrumlu beta-laktamaz üreten enterik basillerin prevalansi ve antibiyotik duyarhliklarinin araştinlmasi. Infeksiyon Derg 2005; 19(1): 111-4.
15. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6(9): 460-3. (Pubitemid 34966064)
16. Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother 2001; 45(10): 2831-7. (Pubitemid 32906679)
17. Mody RM, Erwin DP, Summers AM, et al. Ertapenem susceptibility of extended spectrum beta-lactamaseproducing organisms. Ann Clin Microbiol Antimicrob 2007; 6: 6.
18. Tunçcan ÖG, Keten DT, Dizbay M, Hizel K. Hastane kaynakh Escherichia coli ve Klebsiella susjarimn ertapenem ve diǧer antibiyotiklere duyarliliǧi. ANKEM 2008; 22(4): 188-92.
19. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004; 53(Suppl2):ii11-21.
20. Goldstein EJ, Snydman DR. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004; 53(Suppl 2): ii29-36.
21. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinician. J Antimicrob Chemother 2004; 53(Suppl 2): ii23-8.
22. Tice AD. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. J Antimicrob Chemother 2004; 53(Suppl 2): ii83-6.
23. Alhambra A, Cuadros JA, Cacho J, Gómez-Garcés JL, Alos JI. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004; 53(6): 1090-4.
24. Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American Medical Centers. Antimicrob Agents Chemother 2001; 45(6): 1915-8.
25. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352(4): 380-91.
26. McGuinn M, Hershow RC, Janda WM. Escherichia coli and Klebsiella pneumoniae carbapenemase in longterm care facility, Illinois, USA. Emerg Infect Dis 2009; 15(6): 988-9.
27. Smith Moland E, Hanson ND, Herrera VL, et al. Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2 in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003; 51 (3): 711-4. (Pubitemid 36336168)
28. Bratu S, Quale J. Global emergence of nosocomial gram-negative pathogens possessing carbapenem hydrolyzing ß-lactamases. J Biol Sci 2006; 6(3): 434-45.
29. Aktas Z, Bal C, Midilli K, Poirel L, Nordmann P. First IMP-1 -producing Klebsiella pneumoniae isolate in Turkey. Clin Microbiol Infect 2006; 12(7): 695-6. (Pubitemid 43842497)
30. Livermore DM, Carter MW, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001; 45(6): 1860-7.
31. Mena A, Plasencia V, Garcia L, et al. Characterization of a large outbreak by CTX-M-1 producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol 2006; 44(8): 2831-7. (Pubitemid 44228577)
32. Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K.pneumoniae to upstate New York. Clin Infect Dis 2006; 43(3): e26-8.
33. Karaoǧlan I, Zer Y, Süner A, Namiduru A. Bazi Enterobacteriaceae türlerine ertapenemin in-vitro etkinliǧi ANKEM 2008; 22(4):183-7.